RTK Group

RTK Group is a biopharmaceutical advisory and investment fund focused on supporting companies developing technologies with disruptive impact and significant potential to benefit patients. The firm leverages its expertise in company formation and technology development to assist high-performing management teams in realizing the full value potential of their technology. RTK Group embraces scientific risk and supports research with high-impact potential, believing that investing in promising concepts backed by solid science creates the potential for significant value creation. The ultimate goal is to improve the human condition through support of technology development, fostering scientific innovation and teams dedicated to improving patient lives.

In June 2022, RTK Group participated in the seed-round capital funding of Unravel Biosciences, Inc., a company developing a proprietary drug discovery and patient stratification platform targeting central nervous system orphan diseases like Rett Syndrome. The financial terms of the transaction were not disclosed. This investment expanded RTK Group's biopharma investment portfolio into startups developing platform technologies with high potential for disruptive innovation.

In January 2023, RTK Group joined the Massachusetts Biotechnology Council (MassBio), a move expected to enhance its mission to support the development of promising technology to improve patient lives. MassBio is known for encouraging partnerships and conversations to advance breakthrough science and technology in the biotech and biopharma ecosystem in Massachusetts. RTK Group's membership signifies its commitment to fostering scientific innovation and supporting teams dedicated to improving patient lives.